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94 Poster Session-I3 or 4 weeks before HSCT and continued until discharge. All mi-
crobes including normal flora were specified and their susceptibility
profiles to antimicrobial agents were examined. The sensitivity for
the surveillance culture was defined as the rate of detecting microbes
identical to pathogens of septicemia from throat or feces at least 1
week before the development of septicemia.
Results: Causative pathogens were gram-positive cocci (GPC)
in 19, gram-positive rods (GPR) in 5, and gram-negative rods
(GNR) in 16 episodes. The sensitivity for surveillance cultures
in detecting causative pathogens of septicemia prior to the devel-
opment of septicemia was 42.5% (17 of 40) in all episodes. The
sensitivity was 73.7% (14 of 19) in the septicemia due to GPC,
which was significantly higher than that due to GNR (18.8%; 3
of 16, p\ 0.01).
Conclusions: We conclude that weekly surveillance culture is
useful in predicting the pathogen causing septicemia, particularly
in septicemia due to GPC, after allogeneic HSCT.258
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(FB) CONDITIONING WITH AND WITHOUT TOTAL BODY IRRADIATION
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HC is a recognized complication of HSCT, commonly associ-
ated with the use of cyclophosphamide. Ninety one patients under-
went non-cyclophosphamide, intravenous FB conditioning for
HSCT (autologous [AUTO], n 5 11; matched unrelated donor
[MUD], n 5 42; matched related donor [MRD], n 5 38) at our
institution from February 2005 to September 2008. The condi-
tioning regimen consisted of fludarabine 50 mg/m2 /day (5 days),
busulfan 3.2 mg/kg/day (4 days) with or without TBI (200 cGy x
2). Urine was tested for BK virus using electron microscopy or
polymerase chain reaction in most patients who developed HC.
Twenty seven patients received FB with TBI (AUTO, n 5 4,
MUD, n 5 7, MRD, n 5 16) whereas 64 patients received FB
without TBI (AUTO, n 5 7, MUD, n 5 35, MRD, n 5 22). Me-
dian age was 48.6 years (range: 22–81); male: female ratio was
1.7:1. 17% patients developed HC within one year of transplanta-
tion. 6/27 (22%) of patients who received FB with TBI developed
HC whereas 10/64 (16%) of those that received FB alone devel-
oped HC. All patients who developed HC had an allogeneic trans-
plant (MUD, n 5 8; MRD, n 5 8). The median time to
presentation was 36 days post transplant (range: 14–67). HC cases
were graded as follows: grade 1(n 5 4), grade 2(n 5 9), grade 3(n
5 2), grade 4(n 5 1). BKViruria was detected in 12/16 (75%) of
patients with HC. Acute graft versus host disease grade 2–4 was
seen in 4/16 patients. 1/16 patient required urological intervention
(bilateral ureteral stent placement), the rest were treated conserva-
tively. There was no mortality from HC. Addition of TBI to the
FB regimen did not increase the incidence of HC (p 5 0.29).
HC appears to be associated with allogeneic HSCT. HC was
mild to moderate (grade 1–3) in most patients. The late onset of
HC, in our study, suggests that the causative agent was reactivation
of BKV and not direct toxicity from the conditioning regimen,
which typically causes early onset HC.Patient Characteristics and their Association with HC
Patients (n) HC, n (%) P valueAUTO 11 0
MRD 38 8 (21) 0.29
MUD 42 8 (19)
Patient age, years
#48 34 5 (14) 0.047
$48 57 11 (19)Conditioning Regimen
FB 64 10 (16) 0.29
FB 1TBI 27 6 (22)259
A PILOT STUDY OF PROPHYLACTIC LIPOSOMAL AMPHOTERICIN B (AM-
BISOME) FOLLOWED BY MICAFUNGIN (MYCAMINE) FOR 100 DAYS
TO PREVENT INVASIVE MOLD INFECTIONS FOLLOWING ALLOGENEIC
STEM CELL TRANSPLANTATION IN PEDIATRIC RECIPIENTS
El-Mallawany, N.K.1, Tallamy, B.1, Fearon, N.1, van de Ven, C.1,
Bhatia, M.1, George, D.1, Satwani, P.1, Cairo, M.S.1,2,3 1Columbia Uni-
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Invasive mold infections (IMI) are a significant cause of infec-
tious mortality post allogeneic stem cell transplant (AlloSCT).
We have previously demonstrated the safety and efficacy of liposo-
mal amphotericin B (AMB) for 100 days post AlloSCT in pediatric
recipients (Roman/Cairo et al PBC, 2008). Although AMB is safe
and effective for prophylaxis against IMI post AlloSCT, its associ-
ated nephrotoxicity results in its discontinuation in .10% of
patients. Micafungin is a broad spectrum antifungal active against
yeasts and molds with a markedly diminished side effect profile.
We initiated a pilot study to determine the efficacy and safety of
sequential AMB and Micafungin for antifungal prophylaxis in
pediatric AlloSCT recipients. Twenty-seven patients were given
AMB (3mg/kg/day) IV from d 0–45 and transitioned to Micafun-
gin (1mg/kg/day) IV at d 45 if \ grade II acute graft-
versus-host-disease (GVHD), until d 100. GVHD prophylaxis
was tacrolimus and mycophenolate mofetil (n 5 21) for all patients
as we have previously described (Osunkwo/Cairo et al BBMT,
2004) except those who received CD-34 selected PBSC (T-de-
pleted) who received tacrolimus only (n 5 6). Median age: 8 years
(1–23). Gender: 9F, 18M. Diagnoses: 5-ALL, 6-AML, 2-NHL,
1-NBL, 1-HLH, 4-SAA, 1-b-Thal, 1-MAS, 4-SCD, 1-FA, 1-ALD.
There were 8 CB donors (7-unrelated, 1-related), 6 UPBSC
donors, 11 RBM donors and 2 URBM donors. Median follow-
up is 203 days. The median switch day to Micafungin was 47.
There were no reported side effects attributable to Micafungin
and no one discontinued Micafungin due to toxicity. The probabil-
ity of developing $ grade II acute GVHD and extensive chronic
GVHD was 22.2% and 6.3%, respectively. The probability of
IMI was zero. There were 2 documented invasive fungal infections
(IFI) with Candida Parapsilosis (7.4%) and no Aspergillus IMI.
One IFI occurred on AMB prior to switching to Micafungin, the
other occurred 51 days after switching to Micafungin. All patients
in this cohort are alive at the time of data analysis. Despite a high
population of 60% unrelated donors with 25% receiving T-de-
pleted sources, these preliminary results suggest successive antifun-
gal prophylaxis with AMB and Micafungin is tolerable and
effective in preventing IMI, especially Aspergillus, during the first
100 days post AlloSCT in pediatric recipients. Larger randomized
studies are needed to compare the sequential combination of
AMB/Micafungin to other standard antifungal prophylaxis
regimens.260
LOW INFECTIOUS COMPLICATION RATES IN HEMATOPOIETIC STEM
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MONITORING SYSTEM
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Life-threatening infections are a common cause of morbidity
and mortality in HSCT recipients. We developed a prospective,
real-time monitoring system for infection reporting and interven-
tion for our inpatient HSCT unit. All positive blood, urine, spu-
tum, skin, and stool cultures as well as Clostridium difficile toxin
tests are reviewed monthly. We use an antibiotic algorithm specific
to our HSCT patients (pts) and an on-going antibiotic restriction
policy has been in place for .25 years. All infections are reviewed
to assess the antimicrobial susceptibility patterns of causative in-
fectious agents and to ensure strict compliance with the antibiotic
algorithm. We performed 995 consecutive HSCT from 1994–
